Critical Advances in the Science and Medicine of Thromboembolic Disease

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

August 15, 2009

Expiration Date:

August 15, 2011

Intended Audience:

The educational activity is designed for all physicians, academicians, researchers, investigators, hospital pharmacists, anticoagulation specialists, hematologists, cardiologists, thrombosis specialists, and program directors from the fields of thrombosis and haemostasis who manage patients with thrombosis-related disorders.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

The following program has been supported by an independent medical educational grant from the BMS/Pfizer Partnership.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Policy on Faculty Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosures:

Stavros V. Konstantinides, MD – Program Co-Chairman
Professor of Medicine
Vice Chairman
Department of Cardiology and Pulmonology
University of Goettingen, Germany

Lecture fees: Bayer HealthCare, Bristol-Myers Squibb, Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, GlaxoSmithKline, sanofi-aventis

John H. Alexander, MD, MHS, FACC- Program Co-Chairman
Associate Professor of Medicine
Division of Cardiovascular Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Research Support: Bristol Myers Squibb, Medtronic Japan, NIH, Portola Pharma, Regado Biosciences, Medicure, Millennium Pharmaceuticals, Momenta Pharma, Schering Plough
Consulting / Honorarium: Adolor, Astra Zeneca, Daiichi Sankyo, Medicure, NIH, Novartis, Pfizer

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular
Program, Brigham and Women’s Hospital and the
VA Boston Healthcare System
Senior Investigator, TIMI Group
Harvard Medical School
Boston, MA

Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company.
This presentation discusses off-label and/or investigational uses of various drugs and devices

Sunil V. Rao, MD
Director of Interventional Cardiology
Veterans Administration Medical Center
Division of Cardiovascular Medicine
Duke University Medical Center
Durham, North Carolina

Consultant: sanofi-aventis, The Medicines Company, Cordis Corporation
Research funding: Cordis Corporation, Momenta Pharmaceuticals, Portola Pharmaceuticals
Off-label uses of drugs/devices will be discussed: Fondaparinux in NSTE ACS, Enoxaparin in PCI, Bivalirudin in NSTE ACS

Program Managers and Disclosures

Gideon Bosker, MD
Nothing to Disclose

Milo Falcon
Nothing to Disclose

Denise Leary
Nothing to Disclose

Educational Objectives:

As a result of participating in this program, clinicians from multiple disciplines, including oncology, hematology, surgical oncology, cancer supportive care, cancer nursing, internal medicine, clinical pharmacy, and related specialties will:

• Learn about advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade and possible implications for prophylaxis of thromboembolic and atherothrombotic events in the setting of ACS (secondary prevention) and atrial fibrillation (residual risk reduction).

• Learn how to evaluate and analyze anticoagulation strategies—alone and in combination with antiplatelet agents and risk factors affecting thromboembolism— across the panvascular, arterial, and venous spectrum.

• Learn about advances in oral anticoagulation based on new mechanisms involving inhibition of the coagulation cascade and possible implications for prophylaxis of VTE in multiple settings.

• Learn how to balance the risks and benefits of employing triple therapy—including two antiplatelet agents plus systemic anticoagulation—in the setting of patients who require secondary prevention following an acute, atherothrombotic cardiovascular event (ACS).

• Learn about the mechanisms involved in thromboembolic prevention and the rationale for identifying agents with predictable anticoagulation, in the absence of clinical monitoring.

• Learn about current ACCP, ACC, AHA, ESC, and AAN guidelines for stroke and MI prevention in the setting of AF and CAD.
  

Disclaimer:

Copyright © 2009 by CMEducation Resources, LLC and Pharmatecture, LLC All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2009 All rights reserved